WEST CONSHOHOCKEN, Pa--The Medicines Control Agency, the regulatory
agency for the United Kingdom, has granted a product license for
the marketing of Ethyol (amifostine), manufactured by U.S. Bioscience,
Ethyol is a selective cytoprotective agent indicated for the reduction
of neutropenia-related infection resulting from use of the combination
of cyclophosphamide (Cytoxan, Neosar) and cisplatin (Platinol)
in patients with advanced ovarian carcinoma.
Approval of ethyol in this country suffered a set back when an
advisory committee failed to recommend it to the FDA.